NCT04315129

Brief Summary

Urinary Tract Infection (UTI) is the most common hospital acquired infection worldwide, and is most commonly associated with catheterisation of the bladder. Catheter associated urinary tract infection (CAUTI) causes increased hospital costs, increased length of stay and increased mortality. This burden of disease is, in part, mediated by a lack of diagnostic and monitoring modalities for CAUTI. Both traditional and novel UTI diagnostic tests are susceptible to false positives associated with bacterial colonisation, and correlate poorly with clinically meaningful symptomatic CAUTI. As such, the current standard of care is reliant on clinical monitoring, which is susceptible to diagnostic delays, over and under treatment. Imperial College London have developed a wireless biosensor for continuous monitoring of catheter-urine biochemistry. This project aims to validate this biosensor and demonstrate it's potential for preemptive CAUTI diagnosis through continuous urinary biochemical monitoring.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2018

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

March 18, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 19, 2020

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2021

Completed
Last Updated

September 2, 2021

Status Verified

September 1, 2021

Enrollment Period

3.3 years

First QC Date

March 18, 2020

Last Update Submit

September 1, 2021

Conditions

Keywords

Biosensor

Outcome Measures

Primary Outcomes (1)

  • Time difference of diagnosis

    The time difference of biosensor diagnosis of catheter associated UTI as compared to clinical diagnosis (defined as the prescription time of new antimicrobials for suspected UTI)

    From the time of catheterisation, until 72hours post-removal of catheters.

Secondary Outcomes (4)

  • Sensitivity

    From the time of catheterisation, until 72hours post-removal of catheters.

  • Specificity

    From the time of catheterisation, until 72hours post-removal of catheters.

  • False Positive Rate

    From the time of catheterisation, until 72hours post-removal of catheters.

  • False Negative Rate

    From the time of catheterisation, until 72hours post-removal of catheters.

Study Arms (1)

Single arm

OTHER

A single arm will have biosensor (experimental) diagnoses compared to clinical (control, current standard of care). All participants in this group willl have a biosensor, with the data masked to patients, providers and clinical researchers

Diagnostic Test: Smart Catheter Biosensor

Interventions

A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection

Single arm

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Consent to participate not given Known sensitivity to urinary catheters or electronic products Patients undergoing urologic procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St Mary's Hospital

London, Greater LOndon, W21Y, United Kingdom

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
The biosensors will monitor for infections. As this is an unverified, experimental diagnosis, this will not be made available to the patient or care provider. similarly this will not be available to the clinical researchers in order to avoid observation bias. While the participants, providers and investigators will all be aware that the participants have an active biosensor, they will be blinded to the output thereof.
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: Singlearm blinded study in which biosensor diagnosed infection (experiment) will be compared to clinical diagnosis (control) in a single cohort of surgical patients
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 18, 2020

First Posted

March 19, 2020

Study Start

April 1, 2018

Primary Completion

July 31, 2021

Study Completion

July 31, 2021

Last Updated

September 2, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Participant Data is confidential and will to be shared

Locations